| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 230.2 | 288.2 |
| Gross profit | 148.0 | 169.9 |
| Profit before tax | 27.0 | 29.3 |
| Net income | 0.8 | -28.8 |
| EPS (diluted, $ a share) | $0.00 | $-0.14 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -20.1% |
|---|---|
| Gross margin | 64.3% |
| Operating margin | 18.5% |
10-Q filed with the SEC, NYSE: TRLV. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Trulieve Cannabis Corp.: key numbers
- Share price
- $10.33Close, Nov 16
- Sector
- Life Sciences
- Industry
- Medicinal Chemicals & Botanical ProductsSIC 2833
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Trulieve Cannabis Corp.
All →Trulieve Cannabis Financial Results
Trulieve Cannabis Corp. reported Q3 2026 revenue of $230 million and positive net income of $1 million, marking a significant period following its uplisting to the NYSE. The company highlighted major regulatory milestones, including receiving final DEA registrations for medical marijuana dispensaries and the removal of 280E tax burdens.
“State licensed medical marijuana rescheduling unlocked major milestones including DEA registration, removal of 280E tax, and uplisting to the NYSE. Third quarter results demonstrate the strength of our medical cannabis platform underscored by revenue, margins, and cash generation. With meaningful growth expansion opportunities in Georgia and Texas, we are in the early stages of an accelerated growth cycle.”
Kim Rivers, Trulieve CEO